Lexaria Bioscience Corp. Provides Strategic Update

Stock Information for Relmada Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Relmada Therapeutics Inc.

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference
Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.